Are All Dopamine Agonists Essentially the Same?
- 9 April 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 79 (7), 693-703
- https://doi.org/10.1007/s40265-019-01103-2
Abstract
Dopamine agonists (DAs) represent an excellent treatment option for patients with Parkinson's disease, in both the early and advanced stages of the disease, improving motor symptoms, lowering the incidence of motor complications, and addressing several non-motor symptoms. Indeed, each of these compounds have different pharmacokinetic and pharmacodynamic properties, resulting in a unique efficacy and safety profile. Comorbidities, prominent non-motor symptoms and individual subjects' clinical characteristics should guide the choice of a specific DA, allowing better management of the patient by optimizing the DA benefit/risk ratio. In this article we discuss brain distribution of dopamine receptors and their role in each of the dopaminergic pathways, the pharmacological profile of non-ergoline DAs and class-related adverse effects, as reported from post-marketing studies.Keywords
This publication has 88 references indexed in Scilit:
- Rotigotine Transdermal Patch in Parkinson’s Disease: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson’s diseaseJournal of Neural Transmission, 2013
- Drug Wanting: Behavioral Sensitization and Relapse to Drug-Seeking BehaviorPharmacological Reviews, 2011
- Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER)Movement Disorders, 2010
- Role of Pramipexole in the Management of Parkinsonʼs DiseaseCNS Drugs, 2010
- Effects of Ropinirole Prolonged-Release on Sleep Disturbances and Daytime Sleepiness in Parkinson DiseaseClinical Neuropharmacology, 2010
- Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover studyCurrent Medical Research and Opinion, 2008
- Effects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in ratsClinical and Experimental Pharmacology and Physiology, 2004
- Clinical Pharmacokinetics of RopiniroleClinical Pharmacokinetics, 2000
- Peripheral cardiovascular dopamine receptorsGeneral Pharmacology: The Vascular System, 1977